Greater Cannabis Company (GCAN) Cash from Operations Growth (1y) (2018 - 2026)
Greater Cannabis Company (GCAN) Cash from Operations Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.60 Bn | 87.73 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.91 Bn | 32.16 Bn | 1.97 Bn | 61.90% |
| 3 | Zoetis | 32.46 Bn | 30.52 Bn | 1.62 Bn | -22.14% |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn | 8.20% |
| 5 | United Therapeutics | 23.13 Bn | 20.98 Bn | 648.10 Mn | 0.46% |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.28 Bn | 18.48 Bn | 1.16 Bn | -27.49% |
| 8 | Neurocrine Biosciences | 17.75 Bn | 16.43 Bn | 800.70 Mn | 125.00% |
| 9 | Elanco Animal Health | 12.60 Bn | 12.18 Bn | 785.00 Mn | 425.00% |
| 10 | Greater Cannabis Company | 236,233.75 | 234,794.75 | - | 60.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 60.77% |
| Dec 31, 2025 | -391.25% |
| Sep 30, 2025 | 70.29% |
| Jun 30, 2025 | 60.21% |
| Mar 31, 2025 | 70.28% |
| Dec 31, 2024 | 84.96% |
| Sep 30, 2024 | 56.24% |
| Jun 30, 2024 | -353.52% |
| Mar 31, 2024 | -103.15% |
| Dec 31, 2023 | -71.39% |
| Sep 30, 2023 | -86.47% |
| Jun 30, 2023 | 80.84% |
| Mar 31, 2023 | -86.05% |
| Dec 31, 2022 | 75.82% |
| Sep 30, 2022 | 69.54% |
| Jun 30, 2022 | -49.22% |
| Mar 31, 2022 | 78.52% |
| Dec 31, 2021 | -172.52% |
| Sep 30, 2021 | -45.48% |
| Jun 30, 2021 | 52.64% |